ServiceNow Inc (NOW) Stock Price Today
Aura AI Summary
Key Stats
- $138.55BMarket Cap
- 8,987,668Volume
- TechnologySector
- $189.2652W High
- $83.0052W Low
- 53 DaysTypical Hold Time
- $142.34BEnterprise Value
- -Div Yield
- 67% Sell | 33% BuyTrading Activity
Track ServiceNow Inc (NOW) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, ServiceNow Inc has traded between a low of $83 and a high of $189.26, highlighting its annual price range. Buy and sell ServiceNow Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Most Recent News
Nexalin, Armada, Roze AI, Mattel, and Accenture lead market gains on key deals and earnings beats
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...

Boeing shares rise as new union contract secures 737 production and avoids strike risk.
Boeing's stock rose following the approval of a new four-year union contract covering 13,000 engineers and 4,000 technical workers. The agreement prevents a potential strike that could have disrupted 737 production and delayed aircraft deliveries, pr...

Foghorn Therapeutics cuts price target after ending Lilly partnership and cutting 40% workforce
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.